These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 32096671)

  • 1. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
    Phan K; Phan S; Shumack S; Gupta M
    J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non-segmental vitiligo.
    Yousefian F; Yadlapati S; Browning JC
    J Cosmet Dermatol; 2023 Mar; 22(3):1105-1107. PubMed ID: 36440703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
    Relke N; Gooderham M
    J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo.
    Pranić S; Pulumati A; Vuković D
    Syst Rev; 2024 Apr; 13(1):110. PubMed ID: 38641831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review.
    Utama A; Wijesinghe R; Thng S
    Int J Dermatol; 2024 Aug; 63(8):1020-1035. PubMed ID: 38610078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo.
    Gianfaldoni S; Tchernev G; Wollina U; Roccia MG; Fioranelli M; Lotti J; Rovesti M; Satolli F; Valle Y; Goren A; Tirant M; Situm M; Kovacevic M; França K; Lotti T
    Open Access Maced J Med Sci; 2018 Jan; 6(1):46-48. PubMed ID: 29483979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
    Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
    Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of NB-UVB on noncultured melanocyte and keratinocyte transplantation in treatment of generalized vitiligo using two different donor-to-recipient ratios.
    Tawfik YM; Abd Elazim NE; Abdel-Motaleb AA; Mohammed RAA; Tohamy AMA
    J Cosmet Dermatol; 2019 Apr; 18(2):638-646. PubMed ID: 30280485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic and targeted therapeutics in vitiligo.
    Karagaiah P; Schwartz RA; Lotti T; Wollina U; Grabbe S; Goldust M
    J Cosmet Dermatol; 2023 Jan; 22(1):64-73. PubMed ID: 35029034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis.
    Li R; Qiao M; Wang X; Zhao X; Sun Q
    Photodermatol Photoimmunol Photomed; 2017 Jan; 33(1):22-31. PubMed ID: 27696531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence.
    Sardana K; Muddebihal A; Khurana A
    Expert Rev Clin Pharmacol; 2023; 16(12):1221-1227. PubMed ID: 37982238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcome and persistence of repigmentation from narrow-band ultraviolet B phototherapy in vitiligo.
    Silpa-Archa N; Weerasubpong P; Junsuwan N; Yothachai P; Supapueng O; Wongpraparut C
    J Dermatolog Treat; 2019 Nov; 30(7):691-696. PubMed ID: 30474443
    [No Abstract]   [Full Text] [Related]  

  • 14. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
    Qi F; Liu F; Gao L
    Front Immunol; 2021; 12():790125. PubMed ID: 34868078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
    Olamiju B; Craiglow BG
    Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of local prostaglandin analogues for vitiligo treatment: a systematic review and meta-analysis.
    Chang HC; Guo SP
    Expert Rev Clin Pharmacol; 2022 Mar; 15(3):341-349. PubMed ID: 35473496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient.
    Berbert Ferreira S; Berbert Ferreira R; Neves Neto AC; Assef SMC; Scheinberg M
    Case Rep Dermatol; 2021; 13(1):190-194. PubMed ID: 34703426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
    Kang C
    Drugs; 2024 May; 84(5):579-586. PubMed ID: 38625661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK inhibitors for the treatment of vitiligo.
    Inoue S; Suzuki T; Sano S; Katayama I
    J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
    Huang MY; Armstrong AW
    Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.